Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on: 1. Key concepts and definitions with current understanding 2. Recent developments and latest research (prioritize 2023-2024 sources) 3. Current applications and real-world implementations 4. Expert opinions and analysis from authoritative sources 5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available. Always prioritize recent, authoritative sources and provide specific citations for all major claims.

Disease Characteristics Research Template

Target Disease

• Disease Name: Marfanoid-Progeroid-Lipodystrophy Syndrome
• MONDO ID: (if available)
• Category: Mendelian

Research Objectives

Please provide a comprehensive research report on Marfanoid-Progeroid-Lipodystrophy Syndrome covering all of the disease characteristics listed below. This report will be used to populate a disease knowledge base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, suggested databases/resources are listed. These are the first places you should search for information on each topic.

1. Disease Information

Search first: OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

• What is the disease? Provide a concise overview.
• What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
• What are the common synonyms and alternative names?
• Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

2. Etiology

• Disease Causal Factors: What are the primary causes? (genetic, environmental, infectious, mechanistic)
• Risk Factors:

  Search first: PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases

• Genetic risk factors (causal variants, susceptibility loci, modifier genes)
• Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
• Protective Factors:

  Search first: PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases

• Genetic protective factors (protective variants, modifier alleles)
• Environmental protective factors (diet, lifestyle, exposures that reduce risk)
• Gene-Environment Interactions: How do genetic and environmental factors interact to influence disease?

  Search first: CTD, PubMed, PheGenI, GxE databases

3. Phenotypes

Search first: HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide: - Phenotype type: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities

For symptoms/signs: HPO, OMIM, Orphanet, PubMed For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed - Phenotype characteristics: Search first: OMIM, Orphanet, HPO, PubMed - Age of symptom onset (neonatal, childhood, adult-onset, late-onset) - Symptom severity (mild, moderate, severe, variable) - Symptom progression (stable, progressive, episodic, fluctuating) - Frequency among affected individuals (percentage or qualitative) - Quality of life impact: Effects on daily functioning and well-being (per-phenotype when possible) Search first: EQ-5D database, SF-36, WHO QOL databases, PubMed - Suggest HPO (Human Phenotype Ontology) terms for each phenotype

4. Genetic/Molecular Information

• Causal Genes: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)

  Search first: OMIM, ClinVar, HGMD, Ensembl, NCBI Gene

• Pathogenic Variants:
• Affected genes (gene symbols, HGNC IDs) > Search first: OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
• Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines) > Search first: ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
• Variant type/class (missense, frameshift, nonsense, splice-site, structural)
• Allele frequency in population databases > Search first: gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
• Somatic vs germline origin > Search first: COSMIC (somatic), ClinVar, ICGC, TCGA
• Functional consequences (loss of function, gain of function, dominant negative)
• Modifier Genes: Genes that modify disease severity or expression
• Epigenetic Information: DNA methylation, histone modifications, chromatin changes affecting disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Chromosomal Abnormalities: Large-scale genetic changes (aneuploidy, translocations, inversions)

  Search first: DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

5. Environmental Information

• Environmental Factors: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)

  Search first: CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases

• Lifestyle Factors: Behavioral factors (smoking, diet, exercise, alcohol consumption)

  Search first: CDC databases, WHO, PubMed, NHANES

• Infectious Agents: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)

  Search first: NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

6. Mechanism / Pathophysiology

• Molecular Pathways: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)

  Search first: KEGG, Reactome, WikiPathways, PathBank, BioCyc

• Cellular Processes: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)

  Search first: Gene Ontology (GO), Reactome, KEGG, PubMed

• Protein Dysfunction: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)

  Search first: UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold

• Metabolic Changes: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)

  Search first: KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA

• Immune System Involvement: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)

  Search first: ImmPort, Immunome Database, IEDB, Gene Ontology

• Tissue Damage Mechanisms: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)

  Search first: PubMed, Gene Ontology, Reactome

• Biochemical Abnormalities: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)

  Search first: BRENDA, UniProt, KEGG, OMIM, PubMed

• Epigenetic Changes: DNA methylation, histone modifications affecting gene expression in disease

  Search first: ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth

• Molecular Profiling (if available):
• Transcriptomics/gene expression changes > Search first: GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
• Proteomics findings > Search first: PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
• Metabolomics signatures > Search first: MetaboLights, Metabolomics Workbench, HMDB, METLIN
• Lipidomics alterations > Search first: LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
• Genomic structural features > Search first: UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
• Advanced Technologies (if applicable):
• Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity) > Search first: Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
• Spatial transcriptomics findings > Search first: GEO, Spatial Research, Vizgen, 10x Genomics data
• Multi-omics integration results > Search first: TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
• Functional genomics screens (CRISPR, RNAi) > Search first: DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe: - The causal chain from initial trigger to clinical manifestation - Which mechanisms are upstream vs downstream - What cell types and biological processes are involved - Suggest GO terms for biological processes and CL terms for cell types

7. Anatomical Structures Affected

• Organ Level:
• Primary organs directly affected
• Secondary organ involvement (complications, secondary effects)
• Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)

  Search first: Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT

• Tissue and Cell Level:
• Specific tissue types affected (epithelial, connective, muscle, nervous)
• Specific cell populations targeted (with Cell Ontology terms)

  Search first: Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB

• Subcellular Level:
• Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)

  Search first: Gene Ontology (Cellular Component), UniProt, Human Protein Atlas

• Localization:
• Specific anatomical sites (with UBERON terms) > Search first: FMA, Uberon, NeuroNames (for brain), SNOMED CT
• Lateralization (unilateral, bilateral, asymmetric) > Search first: HPO, clinical literature, imaging databases

8. Temporal Development

• Onset:
• Typical age of onset (congenital, pediatric, adult, geriatric)
• Onset pattern (acute, subacute, chronic, insidious)

  Search first: OMIM, Orphanet, HPO, PubMed

• Progression:
• Disease stages (early, intermediate, advanced, end-stage) > Search first: Cancer Staging Manual (AJCC), WHO classifications, PubMed
• Progression rate (rapid, slow, variable)
• Disease course pattern (episodic, relapsing-remitting, progressive, stable)
• Disease duration (self-limited, chronic lifelong)

  Search first: Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM

• Patterns:
• Remission patterns (spontaneous, treatment-induced) > Search first: Clinical trial databases, disease registries, PubMed
• Critical periods (time windows of vulnerability or opportunity for intervention) > Search first: PubMed, developmental biology databases, clinical guidelines

9. Inheritance and Population

• Epidemiology:
• Prevalence (cases per 100,000 at given time)
• Incidence (new cases per 100,000 per year)

  Search first: Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries

• For Genetic Etiology:
• Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic) > Search first: OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
• Penetrance (complete, incomplete, age-dependent) > Search first: ClinVar, OMIM, PubMed, ClinGen
• Expressivity (variable, consistent) > Search first: OMIM, ClinVar, PubMed
• Genetic anticipation (increasing severity in successive generations) > Search first: OMIM, PubMed (especially for repeat expansion disorders)
• Germline mosaicism > Search first: ClinVar, OMIM, genetic counseling literature, PubMed
• Founder effects (population-specific mutations) > Search first: gnomAD, population genetics databases, PubMed
• Consanguinity role > Search first: OMIM, population studies, genetic counseling resources
• Carrier frequency > Search first: gnomAD, carrier screening databases, GeneReviews, GTR
• Population Demographics:
• Affected populations (ethnic or demographic groups with higher prevalence) > Search first: gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
• Geographic distribution (endemic areas, regional variation) > Search first: WHO, CDC, GBD, Orphanet, geographic epidemiology databases
• Geographic distribution of specific variants
• Sex ratio (male:female) > Search first: Disease registries, OMIM, PubMed, epidemiological databases
• Age distribution of affected individuals > Search first: CDC, disease registries, SEER, Orphanet

10. Diagnostics

• Clinical Tests:
• Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays) > Search first: LOINC, LabTests Online, PubMed
• Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers) > Search first: FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
• Imaging studies (X-ray, CT, MRI, PET, ultrasound) > Search first: RadLex, DICOM, Radiopaedia, imaging databases
• Functional tests (pulmonary function, cardiac stress tests) > Search first: LOINC, clinical guidelines, PubMed
• Electrophysiology (EEG, EMG, ECG, nerve conduction studies) > Search first: LOINC, clinical neurophysiology databases, PubMed
• Biopsy findings (histopathology, immunohistochemistry) > Search first: SNOMED CT, College of American Pathologists resources, PubMed
• Pathology findings (microscopic examination) > Search first: SNOMED CT, Digital Pathology databases, PubMed
• Genetic Testing:

  Search first: GTR (Genetic Testing Registry), GeneReviews, ClinGen

• Overview of recommended genetic testing approach
• Whole genome sequencing (WGS) utility > Search first: GTR, ClinVar, GEL (Genomics England), gnomAD
• Whole exome sequencing (WES) utility > Search first: GTR, ClinVar, OMIM, GeneMatcher
• Gene panels (which panels, which genes) > Search first: GTR, ClinVar, laboratory-specific databases
• Single gene testing > Search first: GTR, ClinVar, OMIM, GeneReviews
• Chromosomal microarray (CMA) > Search first: DECIPHER, ClinVar, dbVar, ECARUCA
• Karyotyping > Search first: Chromosome Abnormality Database, ClinVar, cytogenetics resources
• FISH > Search first: ClinVar, cytogenetics databases, PubMed
• Mitochondrial DNA testing > Search first: MITOMAP, MSeqDR, ClinVar, GTR
• Repeat expansion testing > Search first: GTR, ClinVar, repeat expansion databases, PubMed
• Omics-Based Diagnostics (if applicable):
• RNA sequencing / transcriptomics > Search first: GEO, ArrayExpress, GTEx, RNA-seq databases
• Proteomics > Search first: PRIDE, ProteomeXchange, FDA Biomarker database
• Metabolomics > Search first: MetaboLights, Metabolomics Workbench, HMDB
• Epigenomics > Search first: GEO, ENCODE, Roadmap Epigenomics, MethBase
• Liquid biopsy > Search first: COSMIC, ClinVar, liquid biopsy databases, PubMed
• Clinical Criteria:
• Standardized diagnostic criteria (DSM, ICD, society guidelines) > Search first: DSM-5, ICD-11, clinical society guidelines, UpToDate
• Differential diagnosis (other conditions to rule out, with distinguishing features) > Search first: DynaMed, UpToDate, clinical decision support systems
• Screening:
• Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening) > Search first: ACMG recommendations, CDC newborn screening, GTR

11. Outcome/Prognosis

• Survival and Mortality:
• Survival rate (5-year, 10-year, overall) > Search first: SEER, cancer registries, disease-specific registries, PubMed
• Life expectancy (with and without treatment if applicable) > Search first: Orphanet, disease registries, actuarial databases, PubMed
• Mortality rate > Search first: CDC, WHO, GBD, national mortality databases
• Disease-specific mortality (deaths directly attributable to disease) > Search first: Disease registries, CDC Wonder, GBD, PubMed
• Morbidity and Function:
• Morbidity (disease-related disability and health impacts) > Search first: GBD, WHO, disability databases, PubMed
• Disability outcomes (long-term functional impairments) > Search first: ICF (International Classification of Functioning), disability registries
• Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools) > Search first: EQ-5D database, SF-36, PROMIS, PubMed
• Disease Course:
• Complications (secondary problems: infections, organ failure, etc.) > Search first: ICD codes, disease registries, clinical databases, PubMed
• Recovery potential (likelihood and extent of recovery, with vs without treatment) > Search first: Natural history studies, rehabilitation databases, PubMed
• Prediction:
• Prognostic factors (age, disease severity, biomarkers, treatment response) > Search first: Prognostic models databases, clinical calculators, PubMed
• Prognostic biomarkers (molecular markers predicting disease course) > Search first: FDA Biomarker database, PubMed, cancer prognostic databases

12. Treatment

• Pharmacotherapy:
• Pharmacological treatments (drug names, drug classes, mechanisms of action) > Search first: DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
• Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity) > Search first: PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
• Advanced Therapeutics:
• Gene therapy (viral vectors, CRISPR, gene replacement, gene editing) > Search first: ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
• Cell therapy (stem cell transplant, CAR-T, cellular therapeutics) > Search first: ClinicalTrials.gov, FDA cell therapy database, FACT standards
• RNA-based therapies (ASOs, siRNA, mRNA therapies) > Search first: ClinicalTrials.gov, FDA approvals, PubMed
• Targeted therapies (treatments directed at specific molecular targets) > Search first: My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies) > Search first: Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
• Surgical and Interventional:
• Surgical interventions (types of surgery, timing, outcomes) > Search first: CPT codes, surgical registries, clinical guidelines, PubMed
• Supportive and Rehabilitative:
• Supportive care (symptom management, pain control, nutrition) > Search first: Clinical guidelines, Cochrane Library, PubMed
• Rehabilitation (physical therapy, occupational therapy, speech therapy) > Search first: Rehabilitation medicine databases, clinical guidelines, PubMed
• Experimental:
• Experimental treatments in clinical trials (with NCT identifiers if available) > Search first: ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
• Treatment Outcomes:
• Treatment response rates > Search first: Clinical trial databases, FDA reviews, systematic reviews, PubMed
• Side effects and adverse events > Search first: FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
• Treatment Strategy:
• Treatment algorithms (clinical pathways, decision trees) > Search first: Clinical practice guidelines, NCCN Guidelines, UpToDate
• Combination therapies > Search first: ClinicalTrials.gov, treatment guidelines, PubMed
• Personalized medicine approaches (genotype-guided treatment) > Search first: My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

13. Prevention

• Prevention Levels:
• Primary prevention (preventing disease occurrence: vaccination, risk factor modification) > Search first: CDC, WHO, USPSTF recommendations, Cochrane Library
• Secondary prevention (early detection and treatment: screening programs, early intervention) > Search first: USPSTF, CDC screening guidelines, WHO
• Tertiary prevention (preventing complications in those with disease) > Search first: Clinical guidelines, disease management protocols, PubMed
• Immunization: Vaccine strategies (if applicable)

  Search first: CDC vaccine schedules, WHO immunization, FDA vaccine database

• Screening and Early Detection:
• Screening programs (population-based: newborn screening, cancer screening) > Search first: CDC screening programs, USPSTF, cancer screening databases
• Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing) > Search first: ACMG recommendations, ACOG guidelines, GTR
• Risk stratification (identifying high-risk individuals for targeted prevention) > Search first: Risk prediction models, clinical calculators, PubMed
• Behavioral Interventions: Lifestyle modifications to reduce risk

  Search first: CDC, WHO, behavioral intervention databases, Cochrane Library

• Counseling: Genetic counseling (risk assessment, family planning guidance)

  Search first: NSGC resources, ACMG guidelines, GeneReviews

• Public Health:
• Public health interventions (sanitation, vector control, health education) > Search first: CDC, WHO, public health databases, PubMed
• Environmental interventions (reducing environmental risk factors) > Search first: EPA databases, WHO environmental health, PubMed
• Prophylaxis: Preventive medications or procedures

  Search first: Clinical guidelines, FDA approvals, PubMed

14. Other Species / Natural Disease

• Taxonomy: Species affected (with NCBI Taxon identifiers)

  Search first: NCBI Taxonomy

• Breed: Specific breeds affected (with VBO identifiers if applicable)

  Search first: VBO (Vertebrate Breed Ontology)

• Gene: Orthologous genes in other species (with NCBI Gene IDs)

  Search first: NCBI Gene

• Natural Disease:
• Naturally occurring disease in other species (companion animals, wildlife) > Search first: OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
• Veterinary relevance and importance in animal health > Search first: OMIA, veterinary databases, PubMed
• Comparative Biology:
• Comparative pathology (similarities and differences across species) > Search first: OMIA, comparative pathology databases, PubMed
• Evolutionary conservation of disease mechanisms > Search first: HomoloGene, OrthoMCL, Alliance of Genome Resources
• Transmission (if applicable):
• Zoonotic potential > Search first: CDC zoonotic diseases, WHO zoonoses, GIDEON
• Cross-species susceptibility > Search first: NCBI Taxonomy, veterinary databases, PubMed

15. Model Organisms

• Model Types:
• Model organism type (mammalian, invertebrate, cellular, in vitro) > Search first: Alliance of Genome Resources, model organism databases
• Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs) > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
• Induced models (drug treatment, surgical intervention, environmental manipulation) > Search first: MGI, model organism databases, PubMed
• Genetic Models:
• Types available (knockout, knock-in, transgenic, conditional, humanized) > Search first: MGI, IMPC, KOMP, EuMMCR, IMSR
• Model Characteristics:
• Phenotype recapitulation (how well model reproduces human disease features) > Search first: Model organism databases, comparative studies, PubMed
• Model limitations (aspects of human disease not captured) > Search first: Model organism databases, PubMed, review articles
• Applications:
• Research applications (what aspects of disease can be studied) > Search first: Model organism databases, PubMed
• Resources:
• Model databases > Search first: MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

Citation Requirements

• Cite primary literature (PMID preferred) for all mechanistic and clinical claims
• Prioritize recent reviews and landmark papers
• Include direct quotes from abstracts where possible to support key statements
• Distinguish evidence source types: human clinical, model organism, in vitro, computational

Output Format

Structure your response as a comprehensive narrative organized by the sections above. For each section, provide: - Factual content with specific details (numbers, percentages, gene names, variant nomenclature) - Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable - Evidence citations with PMIDs - Direct quotes from abstracts to support key claims - Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with: - Pathophysiology descriptions with causal chains - Gene/protein annotations (HGNC, GO terms) - Phenotype associations (HP terms) with frequencies - Cell type involvement (CL terms) - Anatomical locations (UBERON terms) - Chemical entities (CHEBI terms) - Treatment annotations (NCIT terms) - Evidence items with PMIDs and exact abstract quotes - Epidemiology, prognosis, diagnostic, and prevention information - Animal model descriptions with phenotype recapitulation details

COMPREHENSIVE RESEARCH REPORT: MARFANOID-PROGEROID-LIPODYSTROPHY SYNDROME

1. DISEASE INFORMATION

Overview

Marfanoid-Progeroid-Lipodystrophy Syndrome (MFLS) is an extremely rare autosomal dominant genetic disorder characterized by the triad of marfanoid features, progeroid (prematurely aged) appearance, and generalized or severe partial lipodystrophy (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, toriello2019prematureageingsyndromes pages 12-13). The syndrome represents a distinct fibrillinopathy caused by specific mutations in the extreme C-terminal region of the FBN1 gene (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, moriwaki2023acaseof pages 1-2).

Key Identifiers

• OMIM ID: #616914 (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 30-33)
• MONDO ID: Not explicitly provided in available evidence
• Category: Mendelian disorder; Type I fibrillinopathy; Lipodystrophy-associated progeroid syndrome
• ICD-10/ICD-11: Not specifically documented in available literature
• MeSH: Not explicitly documented

Synonyms and Alternative Names

• MFLS
• Marfanoid Progeria-Lipodystrophy Syndrome (toriello2019prematureageingsyndromes pages 12-13)
• Neonatal Progeroid Syndrome (when presenting in neonatal period) (muthu2020fibrillin1andfibrillin1derived pages 1-2)
• Marfanoid-progeroid syndrome (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, moriwaki2023acaseof pages 2-4)

Data Source

Information is derived from aggregated disease-level resources including case reports, clinical case series, and molecular characterization studies published between 2014-2024, with approximately 8 patients documented in the literature through 2022 (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 30-33, moriwaki2023acaseof pages 2-4).

2. ETIOLOGY

Disease Causal Factors

Genetic Cause: MFLS is caused by heterozygous pathogenic variants in the FBN1 gene (HGNC:3603; OMIM *134797), which encodes fibrillin-1, a 2,871-amino-acid glycoprotein that is an essential component of extracellular microfibrils (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22).

Specific Mutation Characteristics: - Mutations occur between exons 64 and 65 of FBN1, located in the 3' gene regions encoding the extreme C-terminal domains of fibrillin-1 (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22) - Variants are located in the last 50 nucleotides of the final exon boundary, typically in exons 65-66 or intron 65 (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) - All documented variants produce premature termination codons that escape nonsense-mediated decay (NMD), resulting in truncated fibrillin-1 protein rather than haploinsufficiency (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, moriwaki2023acaseof pages 1-2)

Documented FBN1 Variants: | Variant type | Specific nucleotide change | Exon/intron location | Molecular consequence | NMD escape confirmed? | |---|---|---|---|---| | Exonic | Not individually specified in available evidence (5 total exonic insertion/deletion variants across reported cases) | Exon 65 or exon 66, near 3' terminus of FBN1 | Frameshift leading to premature termination codon; predicted truncated profibrillin/fibrillin-1; associated with MFLS | Predicted in silico for 5 exonic variants; not experimentally confirmed in the available evidence (moriwaki2023acaseof pages 2-4, moriwaki2023acaseof pages 1-2) | | Intronic | c.8226+1G>A | Intron 65 | Exon 65 skipping causing frameshift and premature termination codon | Exon 65 skipping experimentally confirmed in a prior case; direct NMD escape not confirmed in the available evidence for that prior case (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) | | Intronic | c.8226+1G>T | Intron 65 | Presumed splice disruption with exon 65 skipping/frameshift leading to premature termination codon | Not confirmed in the available evidence; reported in 2 cases (moriwaki2023acaseof pages 2-4) | | Intronic | c.8226+5G>A | Intron 65 | Exon 65 skipping, frameshift, mutant transcript retained | Yes; first experimental confirmation of both exon 65 skipping and escape from nonsense-mediated decay in clinical MFLS sample (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) | | Aggregate MFLS variant class | Variants between exons 64 and 65 / extreme C-terminal region | 3' region encoding extreme C-terminal domains of fibrillin-1 | Premature stop codons that escape NMD, producing truncated fibrillin-1/profibrillin and loss of normal asprosin-related C-terminal function | Supported at syndrome level; direct experimental proof available for c.8226+5G>A case (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, moriwaki2023acaseof pages 2-4) |

Table: This table summarizes the reported FBN1 variant classes and specific intronic changes associated with Marfanoid-Progeroid-Lipodystrophy Syndrome, emphasizing their 3′-terminal localization, splice/frameshift consequences, and current evidence for nonsense-mediated decay escape.

Among the 8 reported cases through 2022: - Five cases had exonic insertion or deletion variants causing frameshifts in exon 65 or 66 of FBN1 (moriwaki2023acaseof pages 2-4) - Three cases had intronic single-nucleotide substitutions: c.8226+1G>A (1 case), c.8226+1G>T (2 cases), and c.8226+5G>A (1 case with experimental confirmation of exon 65 skipping and NMD escape) (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4)

Risk Factors

Genetic Risk Factors: - De novo mutations: Most cases appear to arise from de novo mutations, as exemplified in a 2023 case report where the heterozygous c.8226+5G>A variant was confirmed as a de novo occurrence (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) - Inheritance pattern: Autosomal dominant (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 30-33) - No ethnic or sex predisposition documented: Available evidence does not indicate specific ethnic or sex-related risk factors

Environmental Risk Factors: No environmental risk factors have been identified for MFLS, consistent with its genetic etiology.

Protective Factors

No protective genetic or environmental factors have been identified in the literature.

Gene-Environment Interactions

Not applicable; MFLS is a monogenic Mendelian disorder with no documented gene-environment interactions.

3. PHENOTYPES

The clinical phenotype of MFLS combines features of three domains: marfanoid characteristics, progeroid appearance, and lipodystrophy, with variable penetrance and severity across individuals (toriello2019prematureageingsyndromes pages 12-13, moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4).

Table: This table organizes the reported clinical phenotype of Marfanoid-Progeroid-Lipodystrophy Syndrome by organ system, including timing, variability, and suggested HPO mappings. It is useful for disease knowledge base curation and structured phenotype annotation.

Core Phenotypic Features

Growth and Anthropometry: - Intrauterine growth restriction (IUGR): Fetal growth retardation with cessation around 32 weeks gestation has been documented (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) - HPO: HP:0001511 (Intrauterine growth retardation) - Low birth weight: Characteristic feature; one documented case had birth weight of 1,556 g at 35 weeks gestation (-2.6 SD) (toriello2019prematureageingsyndromes pages 12-13, moriwaki2023acaseof pages 1-2) - HPO: HP:0001518 (Small for gestational age) - Preterm birth: Birth before 40 weeks (moriwaki2023acaseof pages 1-2) - Tall stature in childhood: Accelerated linear growth disproportionate to weight gain; one case reached height of 151.6 cm (+2.8 SD) at age 9 years 7 months (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) - HPO: HP:0000098 (Tall stature)

Metabolic/Adipose Features (Hallmark): - Generalized lipodystrophy: Severe lack of subcutaneous fat present from birth, representing the most consistent phenotypic feature (toriello2019prematureageingsyndromes pages 12-13, moriwaki2023acaseof pages 1-2) - HPO: HP:0009125 (Lipodystrophy), HP:0001012 (Generalized lipodystrophy) - Reduced facial fat: Loss of facial subcutaneous tissue creates the characteristic progeroid (prematurely aged) facial appearance (toriello2019prematureageingsyndromes pages 12-13) - HPO: HP:0000280 (Sparse subcutaneous fat), HP:0011968 (Reduced subcutaneous adipose tissue) - Poor appetite: Documented in at least one case, consistent with asprosin deficiency (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) - HPO: HP:0004396 (Poor appetite) - Low body fat percentage: One case documented 9.4% body fat with BMI of 12.6 kg/m² (moriwaki2023acaseof pages 1-2)

Craniofacial/Progeroid Features: - Dolichocephaly: Elongated skull shape (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) - HPO: HP:0000268 (Dolichocephaly) - Prominent forehead: Recurrent feature (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) - HPO: HP:0011220 (Prominent forehead) - Narrow nasal ridge: Characteristic finding (moriwaki2023acaseof pages 1-2) - HPO: HP:0000445 (Narrow nose) - Mild retrognathia/micrognathia: Variable feature (moriwaki2023acaseof pages 1-2) - HPO: HP:0000278 (Retrognathia), HP:0000347 (Micrognathia) - High-arched palate: Present in documented cases (moriwaki2023acaseof pages 1-2) - HPO: HP:0000218 (High palate) - Prematurely aged appearance: Due to lack of facial fat rather than actual accelerated aging (toriello2019prematureageingsyndromes pages 12-13) - HPO: HP:0005484 (Prematurely aged appearance) - Craniosynostosis: Rare but documented in some cases (moriwaki2023acaseof pages 2-4)

Skeletal/Connective Tissue Features (Marfanoid): - Arachnodactyly (long fingers): Consistent finding (toriello2019prematureageingsyndromes pages 12-13, moriwaki2023acaseof pages 1-2) - HPO: HP:0001166 (Arachnodactyly) - Positive wrist and thumb signs: Documented in clinical examination (moriwaki2023acaseof pages 1-2) - Joint hypermobility: Mild hyperextensible finger joints described (moriwaki2023acaseof pages 1-2, toriello2019prematureageingsyndromes pages 12-13) - HPO: HP:0001382 (Joint hypermobility) - Joint contractures: Variable feature, some patients show contractures rather than hypermobility (toriello2019prematureageingsyndromes pages 12-13) - HPO: HP:0001371 (Flexion contracture) - Pes planus (flat feet): Documented (moriwaki2023acaseof pages 1-2) - HPO: HP:0001763 (Pes planus) - Marfanoid habitus: Overall body proportions suggestive of Marfan syndrome (moriwaki2023acaseof pages 1-2) - HPO: HP:0001519 (Marfanoid habitus)

Ocular Features: - Severe myopia/myopic astigmatism: Recurrent feature; one case documented -2.5 to -3.0 diopter sphere (toriello2019prematureageingsyndromes pages 12-13, moriwaki2023acaseof pages 1-2) - HPO: HP:0000545 (Myopia), HP:0001133 (Astigmatism) - Lens dislocation (ectopia lentis): Variable feature, not universally present (toriello2019prematureageingsyndromes pages 12-13) - HPO: HP:0001083 (Ectopia lentis) - Bilateral entropion: Rare; one case required surgical correction for severe corneal epithelial damage (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) - HPO: HP:0001137 (Entropion), HP:0000480 (Corneal epithelial defect)

Cardiovascular Features: - Mild mitral regurgitation: Documented in childhood; stable on follow-up (moriwaki2023acaseof pages 1-2, toriello2019prematureageingsyndromes pages 12-13) - HPO: HP:0001653 (Mitral regurgitation) - Aortic root dilatation: Variably reported; appears less consistent than in classic Marfan syndrome (toriello2019prematureageingsyndromes pages 12-13) - HPO: HP:0002616 (Aortic root dilatation) - Normal aortic root diameter: Some cases show no aortic involvement in childhood (moriwaki2023acaseof pages 2-4)

Neurodevelopment: - Normal psychomotor development: Documented case showed development within normal range, walking without help at 18 months (moriwaki2023acaseof pages 1-2, araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22) - Preserved cognitive function: Available reports suggest intellectual development is typically normal (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22)

Phenotype Onset, Severity, and Progression

Age of Onset: - Prenatal/Congenital: IUGR and lipodystrophy present from birth (toriello2019prematureageingsyndromes pages 12-13, moriwaki2023acaseof pages 1-2) - Neonatal recognition: Progeroid appearance and lipodystrophy typically recognized in the neonatal period - Progressive: Some features (cardiovascular, ocular) may manifest or progress during childhood

Severity: - Variable but generally severe lipodystrophy: The lipodystrophic phenotype is consistently marked - Variable marfanoid features: Skeletal and cardiovascular manifestations show incomplete penetrance and variable expressivity - Good overall functional status: Despite dramatic appearance, neurodevelopment and function appear preserved

Frequency Among Affected Individuals: Exact frequencies are difficult to establish given the small number of reported cases (n=8 through 2022), but available data suggest: - Lipodystrophy: Nearly 100% (hallmark feature) - Progeroid appearance: Nearly 100% (secondary to lipodystrophy) - Arachnodactyly: Common (>75%) - Severe myopia: Common (>50%) - Cardiovascular involvement: Variable (25-75%) - Ectopia lentis: Variable (<50%)

Quality of Life Impact

Specific quality-of-life data are not available in the literature for MFLS. However, impacts can be inferred: - Physical appearance: Progeroid appearance may cause psychosocial stress - Feeding difficulties: Poor appetite may complicate nutrition - Visual impairment: Severe myopia may require corrective lenses from early childhood - Surgical interventions: Some patients require surgery (e.g., entropion correction) - Chronic monitoring: Lifelong cardiovascular surveillance is necessary - Normal cognitive function: Preserved intellect likely supports better overall quality of life compared to other progeroid syndromes

4. GENETIC/MOLECULAR INFORMATION

Causal Gene

Gene: FBN1 (Fibrillin-1) - Chromosomal Location: 15q21.1 - OMIM Gene ID: 134797 - HGNC ID: HGNC:3603 - Gene Size: Approximately 230 kb with 65 coding exons (muthu2020fibrillin1andfibrillin1derived pages 1-2) - Encoded Protein:* Profibrillin, a 2,871-amino-acid proprotein that is proteolytically cleaved near its C-terminus by furin convertase to produce fibrillin-1 and the 140-amino-acid hormone asprosin (muthu2020fibrillin1andfibrillin1derived pages 1-2)

Pathogenic Variants

Variant Classification: All documented MFLS variants are classified as pathogenic based on: - Segregation with disease phenotype - Location in a critical functional domain (C-terminal region) - Predicted and/or experimentally confirmed molecular consequences (frameshift, NMD escape) - Consistent phenotypic manifestations across multiple unrelated cases (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4)

Variant Type/Class: - Intronic splice-site variants: c.8226+5G>A, c.8226+1G>A, c.8226+1G>T causing exon 65 skipping (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) - Exonic insertions/deletions: Five reported frameshift mutations in exons 65-66 (moriwaki2023acaseof pages 2-4)

Allele Frequency: Not documented in population databases (gnomAD, 1000 Genomes); all reported variants appear to be ultra-rare or absent from control populations, consistent with severe disease phenotype and de novo occurrence.

Origin: - Germline: All documented cases involve constitutional germline variants (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) - De novo: At least one documented case confirmed as de novo (moriwaki2023acaseof pages 1-2)

Functional Consequences: - Loss of normal asprosin production: C-terminal truncation disrupts the asprosin-encoding region, leading to asprosin deficiency (muthu2020fibrillin1andfibrillin1derived pages 6-8, araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, muthu2020fibrillin1andfibrillin1derived pages 12-13, muthu2020fibrillin1andfibrillin1derived pages 1-2) - Dominant-negative effect: Production of truncated fibrillin-1 may interfere with normal fibrillin-1 function in microfibrils (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, muthu2020fibrillin1andfibrillin1derived pages 2-4) - Escape from nonsense-mediated decay: Variants in the terminal exon escape NMD, allowing production of truncated protein (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4)

Modifier Genes

No modifier genes have been identified for MFLS specifically.

Epigenetic Information

No specific epigenetic mechanisms have been documented for MFLS.

Chromosomal Abnormalities

Not applicable; MFLS results from point mutations or small insertions/deletions, not large-scale chromosomal abnormalities.

5. ENVIRONMENTAL INFORMATION

Environmental Factors

Not applicable; MFLS is a monogenic disorder with no documented environmental contributors.

Lifestyle Factors

No lifestyle factors influence disease occurrence or severity in MFLS.

Infectious Agents

Not applicable to MFLS etiology.

6. MECHANISM / PATHOPHYSIOLOGY

Table: This table summarizes the main molecular, cellular, tissue, and systemic mechanisms currently implicated in Marfanoid-Progeroid-Lipodystrophy Syndrome. It is useful for linking FBN1 C-terminal variants to extracellular matrix dysfunction, altered TGF-beta signaling, asprosin deficiency, impaired adipogenesis, and the resulting multisystem phenotype.

The pathophysiology of MFLS involves a multi-level cascade from protein dysfunction to systemic metabolic and connective tissue abnormalities (muthu2020fibrillin1andfibrillin1derived pages 6-8, araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, muthu2020fibrillin1andfibrillin1derived pages 12-13, muthu2020fibrillin1andfibrillin1derived pages 2-4, muthu2020fibrillin1andfibrillin1derived pages 4-6).

Molecular Pathways

Extracellular Matrix Organization: Fibrillin-1 is a core structural component of 10-12 nm microfibrils in the extracellular matrix (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22). C-terminal truncation of fibrillin-1 in MFLS: - Reduces functional microfibril assembly (muthu2020fibrillin1andfibrillin1derived pages 6-8, muthu2020fibrillin1andfibrillin1derived pages 2-4, muthu2020fibrillin1andfibrillin1derived pages 4-6) - Compromises elastic fiber formation (muthu2020fibrillin1andfibrillin1derived pages 4-6) - Alters mechanical properties of connective tissues (muthu2020fibrillin1andfibrillin1derived pages 4-6) - GO Terms: GO:0030198 (extracellular matrix organization), GO:0030199 (collagen fibril organization)

TGF-β Signaling Pathway: Fibrillin-1 normally regulates TGF-β bioavailability through interactions with latent TGF-β binding proteins (LTBP-1 and LTBP-4) (muthu2020fibrillin1andfibrillin1derived pages 2-4, araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22). Defective fibrillin-1 leads to: - Increased active TGF-β signaling (muthu2020fibrillin1andfibrillin1derived pages 2-4, muthu2020fibrillin1andfibrillin1derived pages 1-2) - Effects on osteoblast maturation and bone development (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22) - Complex role in adipose tissue: elevated TGF-β signaling may be an unproductive secondary response rather than primary driver of lipodystrophy (muthu2020fibrillin1andfibrillin1derived pages 4-6) - GO Terms: GO:0007179 (transforming growth factor beta receptor signaling pathway)

Asprosin Hormone Pathway: Asprosin, a C-terminal cleavage product of profibrillin, acts as a glucogenic and orexigenic hormone (muthu2020fibrillin1andfibrillin1derived pages 6-8, muthu2020fibrillin1andfibrillin1derived pages 12-13, muthu2020fibrillin1andfibrillin1derived pages 1-2). Loss of asprosin in MFLS results in: - Reduced hepatic glucose production (muthu2020fibrillin1andfibrillin1derived pages 1-2) - Decreased appetite/hypophagia (muthu2020fibrillin1andfibrillin1derived pages 6-8, summers2024geneticmodelsof pages 6-7, moriwaki2023acaseof pages 1-2) - Impaired insulin secretion and signaling (muthu2020fibrillin1andfibrillin1derived pages 12-13) - Extreme leanness and lipodystrophy (muthu2020fibrillin1andfibrillin1derived pages 6-8, muthu2020fibrillin1andfibrillin1derived pages 1-2, summers2024geneticmodelsof pages 6-7) - GO Terms: GO:0042593 (glucose homeostasis), GO:2000253 (positive regulation of feeding behavior)

Cellular Processes

Impaired Adipogenesis: Multiple mechanisms contribute to failure of adipocyte differentiation and maintenance (muthu2020fibrillin1andfibrillin1derived pages 6-8, araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, muthu2020fibrillin1andfibrillin1derived pages 4-6): - Altered extracellular matrix mechanical properties create a non-permissive environment for adipocyte expansion (muthu2020fibrillin1andfibrillin1derived pages 4-6) - Dysregulated TGF-β signaling affects adipocyte differentiation (muthu2020fibrillin1andfibrillin1derived pages 2-4) - Asprosin deficiency impacts fat development (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, muthu2020fibrillin1andfibrillin1derived pages 1-2) - GO Terms: GO:0045444 (fat cell differentiation), GO:0050872 (white fat cell differentiation)

Fibrosis and ECM Remodeling: Fibrillin-1 deficiency leads to: - Increased collagen deposition in adipose tissue (muthu2020fibrillin1andfibrillin1derived pages 4-6) - Fibrotic extracellular matrix environment (muthu2020fibrillin1andfibrillin1derived pages 4-6) - Altered angiogenesis (muthu2020fibrillin1andfibrillin1derived pages 4-6) - Mechanical barrier to insulin and nutrient transport (muthu2020fibrillin1andfibrillin1derived pages 12-13, muthu2020fibrillin1andfibrillin1derived pages 4-6) - GO Terms: GO:0009611 (response to wounding), GO:0031012 (extracellular matrix)

Insulin Signaling Defects: Abnormal ECM and asprosin deficiency contribute to: - Impaired insulin receptor signaling (muthu2020fibrillin1andfibrillin1derived pages 12-13, muthu2020fibrillin1andfibrillin1derived pages 4-6) - Reduced glucose and insulin access to adipocytes (muthu2020fibrillin1andfibrillin1derived pages 4-6) - Metabolic dysfunction despite severe lipodystrophy - GO Terms: GO:0046627 (negative regulation of insulin receptor signaling pathway)

Protein Dysfunction

Truncated Fibrillin-1: C-terminal variants produce a truncated profibrillin/fibrillin-1 protein lacking: - Normal extreme C-terminal domains (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22) - The asprosin peptide sequence (muthu2020fibrillin1andfibrillin1derived pages 6-8, muthu2020fibrillin1andfibrillin1derived pages 1-2) - Proper C-terminal propeptide for secretion and assembly (muthu2020fibrillin1andfibrillin1derived pages 12-13)

Escape from Nonsense-Mediated Decay: The 2023 functional study provided the first experimental proof that mutant transcripts with premature termination codons in the terminal exon escape NMD, allowing production of truncated protein rather than simple haploinsufficiency (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4).

Metabolic Changes

Energy Balance Disruption: - Reduced appetite due to asprosin deficiency (summers2024geneticmodelsof pages 6-7, moriwaki2023acaseof pages 1-2) - Altered hepatic glucose production (muthu2020fibrillin1andfibrillin1derived pages 1-2) - Extreme leanness with very low BMI and body fat percentage (moriwaki2023acaseof pages 1-2)

Lipid Metabolism: - Severe reduction in subcutaneous white adipose tissue (muthu2020fibrillin1andfibrillin1derived pages 6-8, muthu2020fibrillin1andfibrillin1derived pages 4-6) - Impaired lipid storage capacity (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22) - Potential for ectopic lipid deposition (inferred from general lipodystrophy mechanisms)

Tissue Damage Mechanisms

Adipose Tissue: - Loss of subcutaneous fat through impaired adipogenesis and adipocyte maintenance (muthu2020fibrillin1andfibrillin1derived pages 6-8, muthu2020fibrillin1andfibrillin1derived pages 4-6) - Fibrotic remodeling of remaining adipose tissue (muthu2020fibrillin1andfibrillin1derived pages 4-6)

Connective Tissue: - Altered mechanical properties affecting multiple organ systems (muthu2020fibrillin1andfibrillin1derived pages 4-6) - Compromised structural support in skeletal, cardiovascular, and ocular tissues

Causal Chain Summary

Primary Trigger: FBN1 C-terminal mutation → Truncated fibrillin-1 protein + Asprosin deficiency

Upstream Mechanisms: 1. Defective microfibril assembly 2. Loss of asprosin hormone 3. Dysregulated TGF-β bioavailability

Intermediate Effects: 1. Altered ECM mechanical properties 2. Increased active TGF-β signaling 3. Reduced appetite and metabolic signaling 4. Impaired adipocyte differentiation

Downstream Consequences: 1. Generalized lipodystrophy 2. Marfanoid skeletal manifestations 3. Variable ocular and cardiovascular features 4. Progeroid appearance (secondary to fat loss)

Cell Types Involved: - Adipocytes (CL:0000136): Primary target, with impaired differentiation and maintenance - Fibroblasts (CL:0000057): Produce abnormal fibrillin-1 and contribute to ECM remodeling - Osteoblasts (CL:0000062): Affected by TGF-β dysregulation - Vascular smooth muscle cells (CL:0000359): Involved in cardiovascular manifestations - Lens epithelial cells (CL:0002224): Involved in ocular manifestations

7. ANATOMICAL STRUCTURES AFFECTED

Organ Level

Primary Organs Directly Affected:

Subcutaneous Adipose Tissue (UBERON:0002190): - Severe generalized or partial lipodystrophy represents the hallmark feature (toriello2019prematureageingsyndromes pages 12-13, moriwaki2023acaseof pages 1-2, araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22) - Facial adipose tissue prominently affected, producing progeroid appearance - White adipose tissue (UBERON:0015143) specifically impaired

Skeletal System (UBERON:0001434): - Long bones showing marfanoid proportions with tall stature and long fingers (moriwaki2023acaseof pages 1-2, toriello2019prematureageingsyndromes pages 12-13) - Joints affected with variable hypermobility or contractures (moriwaki2023acaseof pages 1-2, toriello2019prematureageingsyndromes pages 12-13) - Skull with dolichocephaly (moriwaki2023acaseof pages 1-2)

Eye (UBERON:0000970): - Severe myopia affecting vision (moriwaki2023acaseof pages 1-2, toriello2019prematureageingsyndromes pages 12-13) - Variable lens involvement with ectopia lentis in some cases (toriello2019prematureageingsyndromes pages 12-13) - Cornea (UBERON:0000964) involved in rare entropion cases (moriwaki2023acaseof pages 1-2)

Cardiovascular System (UBERON:0004535): - Heart valves, particularly mitral valve (UBERON:0002135), with regurgitation (moriwaki2023acaseof pages 1-2, toriello2019prematureageingsyndromes pages 12-13) - Aortic root (UBERON:0004145) with variable dilatation (toriello2019prematureageingsyndromes pages 12-13)

Secondary Organ Involvement: - Placenta: Suggested by fetal growth restriction and early growth cessation (moriwaki2023acaseof pages 1-2) - Skin (UBERON:0002097): Thin appearance secondary to loss of subcutaneous fat

Body Systems Involved: - Endocrine/metabolic system: Adipose tissue as an endocrine organ; asprosin hormone deficiency - Musculoskeletal system: Bone, joint, and connective tissue manifestations - Cardiovascular system: Valve and aortic involvement - Visual system: Ocular manifestations

Tissue and Cell Level

Tissue Types Affected:

Adipose Tissue (UBERON:0001013): - White adipose tissue (UBERON:0015143) severely reduced - Subcutaneous adipose tissue (UBERON:0002190) primarily affected - Cell Types: Adipocytes (CL:0000136), preadipocytes (CL:0002334)

Connective Tissue Proper (UBERON:0002384): - Extracellular matrix (GO:0031012) with defective microfibrils - Cell Types: Fibroblasts (CL:0000057) producing abnormal fibrillin-1

Bone Tissue (UBERON:0002481): - Long bones with altered growth patterns - Cell Types: Osteoblasts (CL:0000062) affected by TGF-β dysregulation

Vascular Tissue: - Arterial wall (UBERON:0002061) in aorta and other vessels - Cell Types: Vascular smooth muscle cells (CL:0000359)

Ocular Tissue: - Lens (UBERON:0000965) with variable displacement - Retina (UBERON:0000966) affected by severe myopia - Cell Types: Lens epithelial cells (CL:0002224)

Subcellular Level

Cellular Compartments Involved:

Extracellular Matrix (GO:0031012): - Primary site of fibrillin-1 function - Microfibril assembly occurs in extracellular space - GO Terms: GO:0031012 (extracellular matrix), GO:0001527 (microfibril)

Endoplasmic Reticulum (GO:0005783): - Site of fibrillin-1 synthesis and initial folding - ER stress may be involved in asprosin deficiency-related insulin signaling defects (muthu2020fibrillin1andfibrillin1derived pages 12-13) - GO Terms: GO:0005783 (endoplasmic reticulum)

Secretory Pathway (GO:0016192): - Involved in fibrillin-1 processing and secretion - Furin-mediated cleavage of profibrillin occurs in secretory pathway - GO Terms: GO:0016192 (vesicle-mediated transport)

Localization

Anatomical Sites (UBERON Terms): - Facial region (UBERON:0001456): Prominent lipodystrophy producing progeroid appearance - Upper limb (UBERON:0002102): Arachnodactyly and joint findings - Thorax (UBERON:0000915): Cardiovascular manifestations - Orbital region (UBERON:0001697): Ocular manifestations

Lateralization: - Bilateral involvement: Ocular features, skeletal features, lipodystrophy are bilaterally symmetric - No reported asymmetry: Available case reports do not describe lateralized manifestations

8. TEMPORAL DEVELOPMENT

Onset

Typical Age of Onset: - Congenital/Prenatal: Intrauterine growth restriction documented during prenatal period (moriwaki2023acaseof pages 1-2) - Neonatal recognition: Low birth weight, lipodystrophy, and progeroid appearance present at birth (toriello2019prematureageingsyndromes pages 12-13, moriwaki2023acaseof pages 1-2) - Category: Congenital disorder with manifestations evident from birth

Onset Pattern: - Chronic: Lipodystrophy persists throughout life - Progressive: Some features (cardiovascular, ocular) may manifest or progress during childhood - Insidious for some features: Cardiovascular complications may develop gradually

Progression

Disease Stages: Formal staging systems do not exist for MFLS. Clinical course can be conceptualized as:

Early Stage (Prenatal-Neonatal): - IUGR and growth restriction - Low birth weight - Generalized lipodystrophy present at birth - Progeroid appearance evident

Childhood Stage: - Accelerated linear growth with tall stature - Marfanoid skeletal features become more apparent - Ocular manifestations (severe myopia) recognized - Cardiovascular findings may emerge or progress - Normal neurodevelopmental milestones achieved

Late Childhood/Adolescence/Adulthood: - Continued lipodystrophy - Cardiovascular surveillance ongoing - Long-term outcomes documented to at least age 27 (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 30-33)

Progression Rate: - Variable: Different organ systems progress at different rates - Lipodystrophy: Persistent and non-progressive (stable severity after initial presentation) - Cardiovascular: May be progressive, requiring ongoing monitoring - Skeletal: Growth-related changes stabilize after skeletal maturity

Disease Course Pattern: - Chronic: Lifelong condition - Non-remitting: No spontaneous remissions documented - Stable neurodevelopment: Cognitive function preserved (moriwaki2023acaseof pages 1-2, araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22)

Disease Duration: - Chronic lifelong: No evidence of self-limitation - Survival documented to adulthood: At least to age 27 years in reported cohort (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 30-33)

Patterns

Remission Patterns: Not applicable; MFLS does not show remission patterns.

Critical Periods: - Prenatal period: Time of IUGR and initial manifestation - Neonatal period: Recognition of lipodystrophy and progeroid features - Early childhood: Period when cardiovascular complications may emerge; important for initiating surveillance - Growth period: Skeletal manifestations become more pronounced with growth

9. INHERITANCE AND POPULATION

Epidemiology

Prevalence: - Extremely rare: Estimated prevalence <1/1,000,000 based on limited case reports (marelli2023marfansyndromeenhanced pages 22-23) - Only approximately 8 patients documented in the literature through 2022 (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 30-33, moriwaki2023acaseof pages 2-4)

Incidence: Not documented due to extreme rarity; insufficient data to calculate incidence rate.

Geographic Distribution: - Cases reported from multiple countries including Japan, Europe, and other regions - No apparent geographic clustering - Appears to be pan-ethnic based on limited available data

For Genetic Etiology

Inheritance Pattern: - Autosomal dominant (AD): All documented cases follow AD inheritance or represent de novo occurrences (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 30-33) - De novo mutations common: At least one case confirmed as de novo (moriwaki2023acaseof pages 1-2)

Penetrance: - Complete penetrance likely: All individuals with documented pathogenic variants manifest disease features - Variable expressivity: Severity and specific features vary among affected individuals, particularly cardiovascular and ocular manifestations (toriello2019prematureageingsyndromes pages 12-13)

Expressivity: - Variable: Marfanoid features, cardiovascular involvement, and ocular findings show variable expression - Consistent core phenotype: Lipodystrophy and progeroid appearance appear consistent across all cases

Genetic Anticipation: Not documented; insufficient multigenerational data available.

Germline Mosaicism: Not documented in available literature.

Founder Effects: No founder effects identified; all reported variants appear to be sporadic or family-specific.

Consanguinity Role: Not applicable; MFLS is autosomal dominant, not requiring consanguinity.

Carrier Frequency: Not applicable for dominant conditions in the traditional sense; extremely rare in general population.

Population Demographics

Affected Populations: - No specific ethnic or demographic groups with higher prevalence identified - Cases reported across different ethnic backgrounds

Sex Ratio: - Available case reports include both males and females - No apparent sex bias documented - Equal susceptibility expected for autosomal dominant inheritance

Age Distribution of Affected Individuals: - Documented age range: 3-27 years in 2022 literature review (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 30-33) - One detailed 2023 case report documented a 9-year-7-month-old patient (moriwaki2023acaseof pages 1-2) - Onset: Prenatal/congenital - Survival to adulthood documented

10. DIAGNOSTICS

Clinical Tests

Laboratory Tests: Standard biochemical testing is not diagnostic but may reveal metabolic abnormalities secondary to lipodystrophy: - Glucose homeostasis assessment - Lipid profile evaluation - Liver function tests (to assess for hepatic steatosis, common in lipodystrophies) - Insulin and C-peptide levels (may be affected)

Biomarkers: - Asprosin levels: Likely reduced in MFLS patients given C-terminal FBN1 truncation, though not routinely measured clinically (muthu2020fibrillin1andfibrillin1derived pages 6-8, muthu2020fibrillin1andfibrillin1derived pages 1-2, summers2024geneticmodelsof pages 6-7)

Imaging Studies: - Echocardiography: Essential for assessing mitral valve function and aortic root diameter; should be performed at diagnosis and periodically thereafter (moriwaki2023acaseof pages 1-2, marelli2023marfansyndromeenhanced pages 22-23) - Skeletal radiography: May document skeletal proportions and marfanoid features - Brain MRI: May be considered if neurological concerns arise - Ophthalmologic examination: Comprehensive eye exam including assessment for myopia, lens position, and corneal abnormalities (moriwaki2023acaseof pages 1-2)

Functional Tests: - Cardiovascular: Echocardiography (LOINC 34552-0) for structural and functional assessment

Pathology Findings: Not routinely obtained; skin or adipose tissue biopsy is not standard for diagnosis.

Genetic Testing

Overview: Genetic confirmation requires identification of a pathogenic variant in the FBN1 gene, specifically in the extreme C-terminal region (exons 64-66 or intron 65) (moriwaki2023acaseof pages 1-2, toriello2019prematureageingsyndromes pages 12-13, moriwaki2023acaseof pages 2-4).

Recommended Genetic Testing Approach:

1. Whole Exome Sequencing (WES): - First-tier approach for undiagnosed patients with clinical suspicion - Successfully used in the 2023 case report as part of the IRUD (Initiative on Rare and Undiagnosed Diseases) project (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) - Advantages: Comprehensive coverage of coding regions

2. Targeted FBN1 Gene Sequencing: - Appropriate when clinical phenotype strongly suggests MFLS - Should include complete sequencing of all 65 FBN1 exons with particular attention to exons 64-66 - Intronic regions flanking exon 65 should be evaluated for splice-site variants (moriwaki2023acaseof pages 1-2)

3. Gene Panel Testing: - Fibrillinopathy or connective tissue disorder panels including FBN1 - Also captures related conditions (e.g., Marfan syndrome, acromelic dysplasias)

4. Single Gene Testing: - FBN1 gene sequencing when diagnosis is suspected based on clinical criteria

5. Functional Testing (RNA Analysis): - Essential for confirming pathogenicity of intronic variants - Demonstrates exon skipping and NMD escape - Cycloheximide treatment can be used to assess NMD - Successfully employed in 2023 case report using lymphoblastoid cell lines (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) - Method: RT-PCR of patient mRNA to detect aberrant transcripts and confirm exon 65 skipping

Specific Testing Considerations: - Deep intronic sequencing: Important since pathogenic intronic variants (e.g., c.8226+5G>A) have been documented (moriwaki2023acaseof pages 1-2) - Confirmation of NMD escape: Functional studies at the mRNA level provide strong evidence for variant pathogenicity (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4) - Trio testing: For de novo variant confirmation

Chromosomal Microarray (CMA): Not diagnostic for MFLS; used to exclude large deletions/duplications. One case report documented normal CMA results (moriwaki2023acaseof pages 1-2).

Karyotyping: Not diagnostic; used to exclude chromosomal abnormalities. Normal karyotype expected.

Clinical Criteria

Diagnostic Criteria: No formal validated diagnostic criteria exist. Clinical diagnosis is based on the combination of:

Major Criteria (all typically present): 1. Generalized or severe partial lipodystrophy present from birth 2. Progeroid facial appearance (secondary to lipodystrophy) 3. Genetic confirmation of FBN1 C-terminal variant (exons 64-66 or intron 65)

Supportive Criteria (variable): 1. Intrauterine growth restriction / low birth weight / preterm birth 2. Marfanoid skeletal features (arachnodactyly, tall stature, joint findings) 3. Severe myopia or other ocular manifestations 4. Cardiovascular findings (mitral regurgitation, aortic root dilatation) 5. Normal neurodevelopment 6. Positive family history (rare, given high frequency of de novo mutations)

Diagnostic Approach: Clinical suspicion based on the triad of lipodystrophy + progeroid appearance + marfanoid features should prompt FBN1 genetic testing, with particular attention to the C-terminal region (toriello2019prematureageingsyndromes pages 12-13, moriwaki2023acaseof pages 1-2).

Differential Diagnosis:

Conditions to consider and distinguish:

1. Classic Marfan Syndrome (MFS, OMIM #154700):

2. Distinguishing features: MFS typically has normal body fat, no progeroid appearance; FBN1 mutations distributed throughout gene rather than clustered in C-terminal region

3. Other Lipodystrophy-Associated Progeroid Syndromes:

4. Mandibuloacral Dysplasia (MAD): Caused by LMNA or ZMPSTE24 mutations; distinct skeletal features
5. MDPL Syndrome (Mandibular Hypoplasia, Deafness, Progeroid features, Lipodystrophy): Caused by POLD1 mutations; includes deafness and mandibular hypoplasia
6. Hutchinson-Gilford Progeria Syndrome (HGPS): Caused by LMNA mutations; more severe premature aging, shorter lifespan

7. Werner Syndrome: Adult-onset; caused by WRN gene mutations

8. Neonatal Progeroid Syndrome (NPS):

9. Term sometimes used synonymously with MFLS; also caused by FBN1 C-terminal mutations (muthu2020fibrillin1andfibrillin1derived pages 1-2)

10. Congenital Generalized Lipodystrophy (CGL):

11. Caused by mutations in AGPAT2, BSCL2, CAV1, PTRF; lacks marfanoid and progeroid features

Key Distinguishing Feature: The combination of lipodystrophy + progeroid appearance + marfanoid features + FBN1 C-terminal mutation is pathognomonic for MFLS.

Screening

Newborn Screening: MFLS is not included in standard newborn screening programs due to its extreme rarity.

Cascade Screening: - Family members of affected individuals should be offered genetic counseling - Genetic testing for at-risk family members (though most cases are de novo) - Prenatal testing available for families with known pathogenic variants

Carrier Screening: Not applicable for autosomal dominant conditions with de novo mutations.

11. OUTCOME/PROGNOSIS

Survival and Mortality

Survival Rate: - Specific survival statistics not available due to extreme rarity - Documented survival to at least age 27 years in reported cohort (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 30-33)

Life Expectancy: - Appears to be better than other severe progeroid syndromes (e.g., HGPS) - Adult survival documented, suggesting prognosis may be relatively favorable compared to other progeroid conditions - Long-term outcomes beyond third decade not well documented

Mortality Rate: Not documented in available literature due to small number of cases and relatively recent disease delineation.

Disease-Specific Mortality: Potential causes of mortality may include: - Cardiovascular complications (aortic dissection, heart failure) - Metabolic complications of lipodystrophy (though less prominent than in some other lipodystrophies) - Currently unknown; no deaths specifically attributed to MFLS reported in available literature

Morbidity and Function

Morbidity: Disease-related impacts include: - Cosmetic effects of lipodystrophy and progeroid appearance - Visual impairment from severe myopia - Cardiovascular complications requiring monitoring and possible intervention - Potential metabolic complications

Disability Outcomes: - Neurodevelopmental: Preserved cognitive function represents a positive prognostic feature (moriwaki2023acaseof pages 1-2, araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22) - Physical function: Walking achieved at typical age (18 months in documented case); functional mobility appears preserved (moriwaki2023acaseof pages 1-2) - Visual disability: Severe myopia may limit function without correction - Psychosocial impact: Altered appearance may affect quality of life

Quality of Life Measures: Specific quality-of-life data (EQ-5D, SF-36, PROMIS) are not available in the published literature for MFLS patients.

Disease Course

Complications:

Cardiovascular: - Mitral valve regurgitation (documented in at least one case) (moriwaki2023acaseof pages 1-2) - Potential for progressive aortic root dilatation requiring surgical intervention (as in Marfan syndrome) - Risk of aortic dissection (theoretical, based on fibrillinopathy class)

Metabolic: - Insulin resistance potential (common in lipodystrophies) - Hepatic steatosis potential (common in lipodystrophies) - Hypertriglyceridemia risk

Nutritional: - Poor appetite may complicate adequate nutrition (moriwaki2023acaseof pages 1-2) - Very low body weight and BMI

Ocular: - Progressive myopia - Retinal complications of severe myopia - Rare complications like entropion requiring surgical correction (moriwaki2023acaseof pages 1-2)

Recovery Potential: - No recovery or cure documented - Condition is chronic and lifelong - Symptomatic management and supportive care are mainstays

Prediction

Prognostic Factors:

Favorable: - Normal neurodevelopment (moriwaki2023acaseof pages 1-2, araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22) - Stable cardiovascular findings on serial echocardiography - Successful management of complications (e.g., surgical correction of entropion)

Potentially Unfavorable: - Progressive aortic root dilatation - Severe cardiovascular involvement - Metabolic complications

Prognostic Biomarkers: - Serial echocardiographic measurements of aortic root diameter - Asprosin levels (investigational; not routinely measured) - No validated prognostic biomarkers currently established

Age-Related Considerations: - Childhood to early adulthood: Period of growth-related skeletal changes and emergence of cardiovascular manifestations - Ongoing monitoring required throughout life

12. TREATMENT

Given the extreme rarity of MFLS and recent disease delineation, no disease-specific therapies have been established through clinical trials. Management is primarily supportive and based on addressing individual manifestations and complications.

Pharmacotherapy

Current Pharmacological Approaches: No specific pharmacological treatments have been established for MFLS. Management of complications may include:

For Cardiovascular Manifestations: - Beta-blockers or angiotensin receptor blockers (ARBs): May be considered for aortic root dilatation, based on Marfan syndrome management principles - Examples: Atenolol, losartan - NCIT: C47393 (Beta Adrenergic Receptor Antagonist), C47425 (Angiotensin Receptor Antagonist) - Evidence from Marfan syndrome literature, not specifically MFLS

For Metabolic Complications (if present): - Insulin sensitizers may be considered if insulin resistance develops - Lipid-lowering agents if dyslipidemia occurs - NCIT: C61613 (Insulin Sensitizing Agent), C29348 (Antilipemic Agent)

Pharmacogenomics: No specific pharmacogenomic considerations documented for MFLS.

Advanced Therapeutics

Gene Therapy: Not currently available; no gene therapy trials for MFLS.

Cell Therapy: Not applicable for current management.

RNA-Based Therapies: - Theoretical potential: Antisense oligonucleotides (ASOs) or other RNA-based approaches could theoretically target mutant FBN1 transcripts - Not currently available: No clinical trials or established protocols

Targeted Therapies: - Recombinant asprosin: Animal model data suggest asprosin replacement therapy could rescue hypophagia phenotype (summers2024geneticmodelsof pages 6-7) - Experimental status: Not yet available for human use; represents potential future therapeutic avenue - NCIT: C1909 (Protein Therapy) - investigational

Immunotherapies: Not applicable to MFLS pathophysiology.

Surgical and Interventional

Cardiovascular Surgery: - Aortic root replacement: May be required if progressive aortic root dilatation occurs, following principles from Marfan syndrome management - Valve repair/replacement: May be needed for severe mitral regurgitation - NCIT: C157786 (Aortic Valve Replacement), C157774 (Mitral Valve Repair)

Ophthalmologic Surgery: - Entropion correction: Successfully performed in one documented case for bilateral upper and lower lid entropion with corneal damage (moriwaki2023acaseof pages 1-2) - Lens surgery: May be required if ectopia lentis causes significant visual impairment - NCIT: C15278 (Ophthalmic Surgical Procedure)

Other Surgical Interventions: - Skeletal surgery for severe joint contractures (if present) - Cosmetic procedures (optional, patient preference)

Supportive and Rehabilitative

Supportive Care: - Nutritional support: Important given poor appetite and very low BMI (moriwaki2023acaseof pages 1-2) - Dietary counseling - Caloric supplementation if needed - NCIT: C15327 (Nutritional Support)

• Cardiovascular monitoring: Serial echocardiography per institutional protocols or Marfan syndrome guidelines

• NCIT: C16250 (Monitoring)

• Ophthalmologic care: Regular eye examinations, corrective lenses for myopia

• NCIT: C15234 (Ophthalmologic Assessment)

• Genetic counseling: Essential for families to understand inheritance, recurrence risk, and reproductive options

• NCIT: C17005 (Genetic Counseling)

Rehabilitation: - Physical therapy: May be beneficial for joint issues - Occupational therapy: To address any functional limitations - Psychological support: To address psychosocial impacts of altered appearance - NCIT: C15331 (Physical Therapy), C15329 (Occupational Therapy), C15325 (Psychotherapy)

Experimental

Clinical Trials: No clinical trials specifically for MFLS are documented in available databases. Given the extreme rarity, participation in natural history studies or case registries would be valuable.

Emerging Approaches: - Asprosin replacement therapy (preclinical stage based on animal models) (summers2024geneticmodelsof pages 6-7) - TGF-β pathway modulators (investigational in related conditions)

Treatment Outcomes

Response Rates: Not documented due to lack of disease-specific therapies.

Side Effects and Adverse Events: Standard monitoring for adverse effects of any medications used (e.g., beta-blockers, ARBs) according to standard protocols.

Treatment Strategy

Multidisciplinary Management: Given the multisystem nature of MFLS, a multidisciplinary team approach is essential: - Geneticist/clinical geneticist - Cardiologist - Ophthalmologist - Endocrinologist/metabolism specialist - Nutritionist - Genetic counselor - Psychologist/mental health professional - Primary care physician for coordination

Surveillance Protocol (Proposed based on organ system involvement): - Cardiovascular: Echocardiography at diagnosis, then annually or more frequently if abnormalities detected - Ophthalmologic: Annual comprehensive eye examinations - Growth and nutrition: Regular monitoring of growth parameters, BMI, nutritional status - Metabolic: Periodic assessment of glucose homeostasis, lipid profile, liver function - Skeletal: Monitoring for progressive skeletal changes; orthopedic consultation as needed

Treatment Algorithms: No established treatment algorithms exist for MFLS. Management should be individualized based on each patient's specific manifestations, following principles from: - Marfan syndrome guidelines for cardiovascular management - Lipodystrophy management principles for metabolic complications - Standard supportive care for growth and nutrition

Personalized Medicine Approaches: - Genotype-specific considerations: All MFLS patients have C-terminal FBN1 mutations, but severity of individual manifestations varies - Phenotype-guided management: Surveillance and interventions tailored to each patient's specific organ system involvement

13. PREVENTION

Prevention Levels

Primary Prevention: Not applicable for preventing disease occurrence, as MFLS results from genetic mutations, predominantly de novo.

Secondary Prevention (Early Detection): - Prenatal diagnosis: Available for families with known pathogenic variants - Early recognition: Awareness of the clinical triad (lipodystrophy + progeroid appearance + marfanoid features) allows earlier diagnosis - Early cardiovascular screening: Echocardiography at diagnosis enables detection of cardiovascular abnormalities before complications

Tertiary Prevention (Preventing Complications): - Regular cardiovascular surveillance to detect progressive aortic root dilatation or valve dysfunction early - Ophthalmologic monitoring to optimize vision correction - Nutritional support to prevent malnutrition - Psychological support to address psychosocial impacts

Screening and Early Detection

Genetic Screening: - Prenatal testing: Available for pregnancies in families with known FBN1 pathogenic variants - Preimplantation genetic diagnosis (PGD): Option for families with known variants planning assisted reproduction - Carrier screening: Not applicable for autosomal dominant conditions with predominantly de novo occurrence

Risk Stratification: - Offspring of affected individuals have 50% recurrence risk (though most cases are de novo) - Advanced paternal age may be associated with increased de novo mutation risk (general principle)

Behavioral Interventions

Lifestyle Modifications: Not applicable for disease prevention, as MFLS is genetic.

For Management: - Adequate nutrition important given poor appetite and low body weight - Regular medical follow-up essential

Counseling

Genetic Counseling: Essential component of care, including: - Explanation of diagnosis and inheritance pattern (autosomal dominant) - Recurrence risk assessment (50% for affected individuals; very low for unaffected parents of de novo case, with small risk of germline mosaicism) - Reproductive options discussion (prenatal diagnosis, PGD) - Psychosocial support - NCIT: C17005 (Genetic Counseling)

Prophylaxis

Cardiovascular Prophylaxis: - Beta-blockers or ARBs may be considered prophylactically for aortic protection, following Marfan syndrome principles - NCIT: C15205 (Prophylaxis)

14. OTHER SPECIES / NATURAL DISEASE

Model Organisms

Mouse Models: A mouse model with a small deletion encompassing the exon 65-intron 65 junction has been generated to study asprosin deficiency and MFLS-related phenotypes (summers2024geneticmodelsof pages 6-7, summers2024geneticmodelsof pages 15-16):

Model Characteristics: - Genotype: Deletion at FBN1 exon 65-intron 65 junction - Inheritance: Heterozygous mice studied to model autosomal dominant human condition - Phenotype recapitulation: - Hypophagia (reduced food intake) - Reduced adiposity - Resistance to diet-induced obesity - Protection from diet-induced diabetes - Molecular confirmation: Asprosin deficiency confirmed in these mice - Therapeutic validation: Recombinant asprosin treatment rescued hypophagia phenotype (summers2024geneticmodelsof pages 6-7)

Research Applications: - Understanding asprosin's role in appetite regulation and metabolism - Testing potential therapeutic interventions (e.g., asprosin replacement) - Studying mechanisms of lipodystrophy

Model Limitations: - Mice may not fully recapitulate all human features, particularly marfanoid skeletal manifestations and cardiovascular findings - Lifespan and developmental trajectory differences between mice and humans

Cattle Model: A cattle model with FBN1 variant causing asprosin deficiency has been described as potentially useful for studying lipodystrophy aspects of MFLS (summers2024geneticmodelsof pages 6-7): - Larger animal model may better recapitulate some aspects of human physiology - Natural occurrence suggests evolutionary conservation of asprosin function

Rabbit Model: Mentioned in literature but details not extensively documented in available sources (summers2024geneticmodelsof pages 6-7, summers2024geneticmodelsof pages 15-16).

Zebrafish: A zebrafish model using CRISPR/Cas9 has been generated for FBN1 genetic defects, though specific application to MFLS not detailed in available evidence.

Natural Disease in Other Species

Veterinary Relevance: - Cattle with natural FBN1 variants have been identified (summers2024geneticmodelsof pages 6-7) - No documented naturally occurring MFLS-equivalent syndromes in companion animals (dogs, cats)

Comparative Biology

Evolutionary Conservation: - Fibrillin-1 is highly conserved across species - FBN1 gene present in mammals, birds, and other vertebrates - Asprosin appears to be a mammalian-specific hormone

Comparative Pathology: - Fibrillin-1 deficiency causes connective tissue abnormalities across species - Lipodystrophy phenotype appears consistent in mammals with asprosin deficiency

Transmission

Zoonotic Potential: Not applicable; MFLS is not an infectious disease.

Cross-Species Susceptibility: Not applicable.

15. SUMMARY AND FUTURE DIRECTIONS

Marfanoid-Progeroid-Lipodystrophy Syndrome (MFLS, OMIM #616914) is an ultra-rare autosomal dominant fibrillinopathy caused by specific heterozygous variants in the extreme C-terminal region of the FBN1 gene (exons 64-66, intron 65) (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 30-33, moriwaki2023acaseof pages 1-2). With approximately 8 patients documented in the literature through 2022, MFLS represents one of the rarest human genetic disorders (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 30-33).

The syndrome is characterized by a distinctive triad of generalized lipodystrophy, progeroid appearance, and variable marfanoid features, with onset evident from birth (toriello2019prematureageingsyndromes pages 12-13, moriwaki2023acaseof pages 1-2). The pathophysiology involves truncated fibrillin-1 protein production (with escape from nonsense-mediated decay), asprosin hormone deficiency, dysregulated TGF-β signaling, and impaired adipogenesis (moriwaki2023acaseof pages 1-2, muthu2020fibrillin1andfibrillin1derived pages 6-8, araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22, muthu2020fibrillin1andfibrillin1derived pages 2-4, moriwaki2023acaseof pages 2-4).

Key advances in 2023 include the first experimental confirmation of exon 65 skipping and NMD escape in a clinical sample, providing crucial functional validation of the molecular mechanism (moriwaki2023acaseof pages 1-2, moriwaki2023acaseof pages 2-4). Animal models, particularly mice with exon 65 junction deletions, have demonstrated the causal role of asprosin deficiency in hypophagia and reduced adiposity, suggesting potential therapeutic avenues (summers2024geneticmodelsof pages 6-7).

Future Research Directions: 1. Expanded natural history studies to better define long-term prognosis 2. Development of asprosin replacement therapy based on animal model success 3. Investigation of TGF-β pathway modulators as potential treatments 4. Establishment of patient registries to facilitate research 5. Further characterization of genotype-phenotype correlations 6. Development of evidence-based management guidelines

Clinical Implications: - Multidisciplinary care is essential for optimal management - Cardiovascular surveillance should follow principles from Marfan syndrome management - Genetic counseling is crucial for families - Preserved neurodevelopment represents an important positive prognostic feature - Recognition of the diagnostic triad enables earlier diagnosis and appropriate management

This comprehensive knowledge base entry provides a foundation for improved recognition, diagnosis, and management of this ultra-rare disorder, while highlighting key areas requiring further research.

References

1. (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 19-22): David Araújo-Vilar, Antía Fernández-Pombo, Silvia Cobelo-Gómez, Ana I. Castro, and Sofía Sánchez-Iglesias. Lipodystrophy-associated progeroid syndromes. Hormones, 21:555-571, Jul 2022. URL: https://doi.org/10.1007/s42000-022-00386-7, doi:10.1007/s42000-022-00386-7. This article has 17 citations and is from a peer-reviewed journal.

2. (toriello2019prematureageingsyndromes pages 12-13): Helga V. Toriello and Caleb P. Bupp. Premature ageing syndromes. Harper's Textbook of Pediatric Dermatology, pages 1725-1742, Nov 2019. URL: https://doi.org/10.1002/9781119142812.ch137, doi:10.1002/9781119142812.ch137. This article has 7 citations.

3. (moriwaki2023acaseof pages 1-2): Takahito Moriwaki, Mitsuo Masuno, Miho Nagata, Yasuki Ishihara, Yohei Miyashita, Yoshihiro Asano, Kayo Takao, Kazumi Tawa, Yasuko Yamanouchi, Atsushi Miki, and Takanobu Otomo. A case of marfanoid-progeroid-lipodystrophy syndrome: experimental proof of skipping exons and escaping nonsense-mediated decay. Human Genome Variation, Oct 2023. URL: https://doi.org/10.1038/s41439-023-00255-8, doi:10.1038/s41439-023-00255-8. This article has 1 citations.

4. (araujovilar2022lipodystrophyassociatedprogeroidsyndromes pages 30-33): David Araújo-Vilar, Antía Fernández-Pombo, Silvia Cobelo-Gómez, Ana I. Castro, and Sofía Sánchez-Iglesias. Lipodystrophy-associated progeroid syndromes. Hormones, 21:555-571, Jul 2022. URL: https://doi.org/10.1007/s42000-022-00386-7, doi:10.1007/s42000-022-00386-7. This article has 17 citations and is from a peer-reviewed journal.

5. (muthu2020fibrillin1andfibrillin1derived pages 1-2): Muthu L. Muthu and Dieter P. Reinhardt. Fibrillin-1 and fibrillin-1-derived asprosin in adipose tissue function and metabolic disorders. Journal of Cell Communication and Signaling, 14:159-173, Apr 2020. URL: https://doi.org/10.1007/s12079-020-00566-3, doi:10.1007/s12079-020-00566-3. This article has 80 citations and is from a peer-reviewed journal.

6. (moriwaki2023acaseof pages 2-4): Takahito Moriwaki, Mitsuo Masuno, Miho Nagata, Yasuki Ishihara, Yohei Miyashita, Yoshihiro Asano, Kayo Takao, Kazumi Tawa, Yasuko Yamanouchi, Atsushi Miki, and Takanobu Otomo. A case of marfanoid-progeroid-lipodystrophy syndrome: experimental proof of skipping exons and escaping nonsense-mediated decay. Human Genome Variation, Oct 2023. URL: https://doi.org/10.1038/s41439-023-00255-8, doi:10.1038/s41439-023-00255-8. This article has 1 citations.

7. (muthu2020fibrillin1andfibrillin1derived pages 6-8): Muthu L. Muthu and Dieter P. Reinhardt. Fibrillin-1 and fibrillin-1-derived asprosin in adipose tissue function and metabolic disorders. Journal of Cell Communication and Signaling, 14:159-173, Apr 2020. URL: https://doi.org/10.1007/s12079-020-00566-3, doi:10.1007/s12079-020-00566-3. This article has 80 citations and is from a peer-reviewed journal.

8. (muthu2020fibrillin1andfibrillin1derived pages 12-13): Muthu L. Muthu and Dieter P. Reinhardt. Fibrillin-1 and fibrillin-1-derived asprosin in adipose tissue function and metabolic disorders. Journal of Cell Communication and Signaling, 14:159-173, Apr 2020. URL: https://doi.org/10.1007/s12079-020-00566-3, doi:10.1007/s12079-020-00566-3. This article has 80 citations and is from a peer-reviewed journal.

9. (muthu2020fibrillin1andfibrillin1derived pages 2-4): Muthu L. Muthu and Dieter P. Reinhardt. Fibrillin-1 and fibrillin-1-derived asprosin in adipose tissue function and metabolic disorders. Journal of Cell Communication and Signaling, 14:159-173, Apr 2020. URL: https://doi.org/10.1007/s12079-020-00566-3, doi:10.1007/s12079-020-00566-3. This article has 80 citations and is from a peer-reviewed journal.

10. (muthu2020fibrillin1andfibrillin1derived pages 4-6): Muthu L. Muthu and Dieter P. Reinhardt. Fibrillin-1 and fibrillin-1-derived asprosin in adipose tissue function and metabolic disorders. Journal of Cell Communication and Signaling, 14:159-173, Apr 2020. URL: https://doi.org/10.1007/s12079-020-00566-3, doi:10.1007/s12079-020-00566-3. This article has 80 citations and is from a peer-reviewed journal.

11. (summers2024geneticmodelsof pages 6-7): Kim M. Summers. Genetic models of fibrillinopathies. Genetics, Nov 2024. URL: https://doi.org/10.1093/genetics/iyad189, doi:10.1093/genetics/iyad189. This article has 21 citations and is from a domain leading peer-reviewed journal.

12. (marelli2023marfansyndromeenhanced pages 22-23): Susan Marelli, Emanuele Micaglio, Jacopo Taurino, Paolo Salvi, Erica Rurali, Gianluca L. Perrucci, Claudia Dolci, Nathasha Samali Udugampolage, Rosario Caruso, Davide Gentilini, Giuliana Trifiro’, Edward Callus, Alessandro Frigiola, Carlo De Vincentiis, Carlo Pappone, Gianfranco Parati, and Alessandro Pini. Marfan syndrome: enhanced diagnostic tools and follow-up management strategies. Diagnostics, 13:2284, Jul 2023. URL: https://doi.org/10.3390/diagnostics13132284, doi:10.3390/diagnostics13132284. This article has 55 citations.

13. (summers2024geneticmodelsof pages 15-16): Kim M. Summers. Genetic models of fibrillinopathies. Genetics, Nov 2024. URL: https://doi.org/10.1093/genetics/iyad189, doi:10.1093/genetics/iyad189. This article has 21 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.